Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
br Materials and methods br
2024-12-05
Materials and methods Results Discussion In the present study, we identified HBP1 as a novel substrate of AKT. This was demonstrated by in vitro phosphorylation assays and western blotting using phosphosite-specific antibodies. Three sites were identified by mass spectrometry and mutagenesi
-
The numbers and types of molecules needing
2024-12-05
The numbers and types of molecules needing to be transported across membranes are very large, and there is a corresponding very large and diverse number of transporters expressed throughout the body. Hundreds of proteins that have been assigned as having transporter function are broadly divided into
-
br STAR Methods br Author Contributions br
2024-12-05
STAR★Methods Author Contributions Acknowledgments We thank Antony M. Dean for initial discussions and encouragement concerning ancestral sequence reconstruction. We also thank Natalie K. Goto for constructive criticism concerning the manuscript, Steven M. Sine for providing luteolin sale r
-
In order to increase the oral bioavailability abiraterone is
2024-12-05
In order to increase the oral bioavailability, abiraterone (157) is being used in the form of its 3β-acetoxy prodrug, abiraterone acetate (156). In spite of the fact that high-fat meals increase the oral Emodepside of abiraterone acetate (156), it is recommended that this drug should be taken on an
-
br Introduction S http www
2024-12-05
Introduction Systemic lupus erythematosus (SLE) is a group of systemic autoimmune disorders characterized by anti-nuclear Silydianin sale (ANA), rashes and photosensitivity, joint inflammation, nephritis, and other clinical criteria. SLE develops through the breakdown of three major checkpoints:
-
In this scenario the receptor tyrosine kinase
2024-12-05
In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; PICI 118,551
-
br Synthetic lethal approaches In
2024-12-04
Synthetic lethal approaches In addition to the potential utility of ATM and ATR as chemo- or radiosensitisers, recent studies suggest that such compounds may have single agent activity in certain subsets of patients through induction of synthetic lethality. Two genes are considered synthetically
-
Recently AFF was used to convert an
2024-12-04
Recently, AFF was used to convert an FN3-based binder specific to the Src homology 2 (SH2) domain of cAbl kinase into an allosterically regulated, intermolecular fluorescent switch (Figure 2D). Binding to cAbl kinase co-operatively stabilized the assembly of the FN3-based binder from two partial fra
-
br Findings br Discussion br
2024-12-04
Findings Discussion Conclusions Midwives were more likely to provide effective antimalaria services (including two doses of IPT during the second and third trimesters of pregnancy) to pregnant women if Conflict of interest Authors’ contributions Funding Acknowledgements Resea
-
The Irbesartan Diabetic Nephropathy Trial enrolled patients
2024-12-04
The Irbesartan Diabetic Nephropathy Trial enrolled patients with type 2 diabetes, proteinuria of at least 0.9 g/24 h, BP >135/85 mmHg and moderate kidney impairment (creatinine 88 to 265 µmol/L in women or 106 to 265 µmol/L in men). Patients were randomized to receive irbesartan (titrated from 75 to
-
The lactam emerged as lead candidate due to its
2024-12-03
The lactam (6) emerged as lead candidate due to its high selectivity, outstanding potency (against ALK or in clinically known ALK mutants), low in vitro clearance, and low efflux potential. The lactam (6) was selected for further profiling against the resistant ALK mutants. Preclinical rat pharmacok
-
To investigate further the clinical and mutational spectrum
2024-12-02
To investigate further the clinical and mutational spectrum associated with -related dyskinesia, we here performed a screen in a large series of patients affected with an unexplained hyperkinetic movement disorder, resulting in the identification of 2 pediatric patients presenting with a novel pheno
-
The activation of P Rs modulates the
2024-12-02
The activation of P1Rs modulates the activity of many ion channels and receptors (Sebastião and Ribeiro, 2009) and the recent detection of P1Rs at the postsynaptic level of the adult NMJ (Garcia et al., 2014) makes potentially possible an adenosine-mediated modulation of the nicotinic Benztropine me
-
br Concluding remarks ROP is a major cause of childhood
2024-12-02
Concluding remarks ROP is a major cause of childhood blindness in the world. Current pharmacological therapy focus on anti-VEGF strategy, but this strategy is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Preclinical studies
-
To our knowledge BAY has not progressed
2024-12-02
To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit
13766 records 10/918 page Previous Next First page 上5页 678910 下5页 Last page